Skip to Content
Merck
All Photos(1)

Key Documents

More Documents

L1920

Sigma-Aldrich

LY255283

≥98% (HPLC), powder

Synonym(s):

1-(5-Ethyl-2-hydroxy-4-(6-methyl-6-(1H-tetrazol-5-yl)heptyloxy)phenyl)ethanone

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C19H28N4O3
CAS Number:
117690-79-6
Molecular Weight:
360.45
MDL number:
MFCD00876422
UNSPSC Code:
12352204
PubChem Substance ID:
329817396
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

off-white to light yellow

solubility

DMSO: >20 mg/mL

originator

Eli Lilly

storage temp.

−20°C

SMILES string

CCc1cc(C(C)=O)c(O)cc1OCCCCCC(C)(C)c2nnn[nH]2

InChI

1S/C19H28N4O3/c1-5-14-11-15(13(2)24)16(25)12-17(14)26-10-8-6-7-9-19(3,4)18-20-22-23-21-18/h11-12,25H,5-10H2,1-4H3,(H,20,21,22,23)

InChI key

WCGXJPFHTHQNJL-UHFFFAOYSA-N

Application

LY255283, a competitive leukotriene B4 receptor antagonist, is used in leukotriene receptor research along with other selective leukotriene receptor agonists and antagonist to identify and differentiate the physiological and cell signaling effects of the leukotriene B4 receptor on processes such as paclitaxel resistance in MCF-7/DOX breast cancer cells, monocyte-derived dendritic cell chemotaxis, and 5-lipoxygenase activity and interleukin-8 production in human neutrophils. LY255283 may be used to help verify that an observed process or cell event is leukotriene B4 receptor-dependent.

Biochem/physiol Actions

LY255283 is a competitive leukotriene B4 receptor antagonist, with an IC50 of about 100 nM. It is somewhat selective for the BLT2 receptor, since IC50 values at the BLT1 receptor are >10 μM. LY255283 reduces airway obstruction in animal models of asthma.

Features and Benefits

This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class Code

11 - Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jin-Wook Lee et al.
The Journal of biological chemistry, 288(42), 30054-30063 (2013-08-30)
The majority of prostate cancer-related deaths are associated with advanced and metastatic malignancies. Although anoikis resistance has been recognized as one of the hallmarks of metastatic prostate malignancies, the molecular events that cause anoikis resistance are poorly understood. In this
J Wijkander et al.
The Journal of biological chemistry, 270(44), 26543-26549 (1995-11-03)
Addition of submicromolar concentrations of arachidonic acid (AA) to human neutrophils induced a 2-fold increase in the activity of a cytosolic phospholipase A2 (PLA2) when measured using sonicated vesicles of 1-stearoyl-2-[14C]arachidonoylphosphatidylcholine as substrate. A similar increase in cytosolic PLA2 activity
Anne-Sofie Johansson et al.
Prostaglandins, leukotrienes, and essential fatty acids, 84(3-4), 109-112 (2010-12-25)
Leukotriene B4 (LTB4), a potent chemotactic and immune-modulating lipid mediator, signals via two receptors, BLT1 and BLT2, leading to pro-inflammatory responses in phagocytes. Recently, we reported that BLT1 is the predominating BLT on human umbilical vein endothelial cells (HUVEC) and
P S Wollert et al.
Surgery, 114(2), 191-198 (1993-08-01)
Polymorphonuclear neutrophils (PMNs) have been implicated in the pathogenesis of the adult respiratory distress syndrome (ARDS). Because leukotriene B4 (LTB4) is a potent activator of PMNs, we sought to determine whether LY255283, an LTB4 receptor antagonist, could block PMN activation
M P Fink et al.
Critical care medicine, 21(12), 1825-1837 (1993-12-01)
To evaluate the hypothesis that treatment with LY255283, a novel leukotriene B4-receptor antagonist, is beneficial in an animal model of the adult respiratory distress syndrome induced by endotoxin. Prospective, randomized, controlled trial. Laboratory at a large university medical center. Twenty-five
View All Related Papers

Related Content

Discover Bioactive Small Molecules for Lipid Signaling Research

Discover Bioactive Small Molecules for Lipid Signaling Research

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service